CMC(SH:603122) Bei Jing Shang Bao·2026-01-25 10:11Core Viewpoint - The company, Hefei China, anticipates a net profit loss of between 36 million yuan and 25 million yuan for the year 2025, indicating a significant decline compared to the previous year [1] Company Performance - The projected loss is attributed to changes in the domestic macro environment and the implementation of centralized procurement policies in the in vitro diagnostic industry, which are reshaping the market competition landscape [1] - The company has experienced a decrease in product procurement prices from hospital clients, leading to fluctuations in order volume compared to the previous year, which poses challenges to sales revenue and gross profit levels [1] Cost Management and Strategic Initiatives - Despite implementing various cost-saving and expense control measures, the company faces fixed expenditures that cannot be proportionately reduced alongside revenue [1] - The company has invested in optimizing its talent structure and building a core talent team to capitalize on opportunities created since the launch of the ACME strategy, resulting in costs related to personnel optimization and capability upgrades [1]